瑛泰医疗(01501)拟斥资1000万美元进一步收购德晋医疗约0.79%股权

智通财经06-25

智通财经APP讯，瑛泰医疗(01501)公布，就公司收购Valgen Holding Corporation已发行股本总额约23.18%，于2026年6月25日，公司(作为买方，或透过其代名人)与目标公司若干现有股东(即卖方)订立进一步股份转让协议，该公司拟向卖方收购目标公司119,545股B轮优先股(进一步销售股份)，占目标公司已发行股本总额约0.79%，总对价为1000万美元(相等于约人民币...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2646801312?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-25 22:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646801312","market":"sh","top_or_hot":-1,"title":"瑛泰医疗(01501)拟斥资1000万美元进一步收购德晋医疗约0.79%股权","media":"智通财经","content":"<div>\n<p>智通财经APP讯，瑛泰医疗(01501)公布，就公司收购Valgen Holding Corporation已发行股本总额约23.18%，于2026年6月25日，公司(作为买方，或透过其代名人)与目标公司若干现有股东(即卖方)订立进一步股份转让协议，该公司拟向卖方收购目标公司119,545股B轮优先股(进一步销售股份)，占目标公司已发行股本总额约0.79%，总对价为1000万美元(相等于约人民币...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1459075.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>瑛泰医疗(01501)拟斥资1000万美元进一步收购德晋医疗约0.79%股权</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n瑛泰医疗(01501)拟斥资1000万美元进一步收购德晋医疗约0.79%股权\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-25 22:54 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1459075.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，瑛泰医疗(01501)公布，就公司收购Valgen Holding Corporation已发行股本总额约23.18%，于2026年6月25日，公司(作为买方，或透过其代名人)与目标公司若干现有股东(即卖方)订立进一步股份转让协议，该公司拟向卖方收购目标公司119,545股B轮优先股(进一步销售股份)，占目标公司已发行股本总额约0.79%，总对价为1000万美元(相等于约人民币...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1459075.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01501","symbol_name":"瑛泰医疗","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1459075.html","article_id":"2646801312","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646801312","pubTimestamp":1782399279,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"据悉，目标公司持有德晋医疗100%股权。其中，DragonFly经导管二尖瓣夹系统为国家药监局批准的首款国产经导管二尖瓣产品。于首次收购事项及第二次收购事项均完成后，公司将合共持有目标公司已发行股本总额约23.97%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159891":"医疗","01501":"瑛泰医疗","BK1222":"医疗保健用品"},"translate_title":"Yingtai Medical (01501) intends to spend US$10 million to further acquire about 0.79% equity of Dejin Medical","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159891":1.5,"01501":1.5},"content_text":"智通财经APP讯，瑛泰医疗(01501)公布，就公司收购Valgen Holding Corporation已发行股本总额约23.18%，于2026年6月25日，公司(作为买方，或透过其代名人)与目标公司若干现有股东(即卖方)订立进一步股份转让协议，该公司拟向卖方收购目标公司119,545股B轮优先股(进一步销售股份)，占目标公司已发行股本总额约0.79%，总对价为1000万美元(相等于约人民币6820.9万元)。据悉，目标公司持有德晋医疗100%股权。目标公司为无实质业务活动的控股公司。德晋医疗主要从事房室瓣疾病方面(尤其是二尖瓣及三尖瓣介入治疗)介入治疗技术及产品的研发、生产及销售。德晋医疗为目标集团在中国的主要经营实体。目标集团自主研发的四款产品已获国家药监局纳入创新医疗器械特别审查程序，分别为MitralStitch®经心尖二尖瓣修复系统、DragonFly™经导管二尖瓣夹系统、DragonFly-T®经导管三尖瓣夹系统及DragonFire®经导管心肌射频消融系统。其中，DragonFly™经导管二尖瓣夹系统为国家药监局批准的首款国产经导管二尖瓣产品。于首次收购事项及第二次收购事项均完成后，公司将合共持有目标公司已发行股本总额约23.97%。董事会认为，收购目标公司的股权为公司提供补充其结构性心脏病领域产品管线的机会，以实现该领域更全面的产品覆盖，并提升集团于心血管介入领域的整体竞争力及长远发展潜力。第二次收购事项旨在落实公司逐步增持目标公司股权的策略。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646801312","isCrawlerRequest":true}